FDA clears 1st imaging platform to select stroke patients for clot removal

The RAPID neuroimaging platform has been cleared by the FDA to use in selecting stroke patients for endovascular thrombectomy. It becomes the first imaging platform to receive such clearance for clot removal procedure, reported the creator of the technology, iSchemaView.

“This FDA clearance confirms RAPID as the de facto standard in neuroimaging, not only for the automated analysis of brain images derived from CT and MRI, but now for the diagnosis and treatment of stroke,” said Don Listwin, CEO of iSchemaView, in a news release.

According to Listwin, RAPID will particularly help physicians in small community hospitals.

“Because RAPID enables stroke treatment decisions that are based on intuitive and easily interpretable real-time views of brain perfusion, physicians will quickly and easily be able to determine which patients can be treated locally and which require urgent transfer to thrombectomy centers—bolstering the capabilities of smaller hospitals and therefore improving patient care,” Listwin said.

The platform contains both RAPID CT-Perfusion and RAPID MR-Perfusion, each available to help physicians determine appropriate thrombectomy patients.